EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function

Matthew R Singer, Tung Dinh, Lev Levintov, Arun S Annamalai, Juan S Rey, Lorenzo Briganti, Nicola J Cook, Valerie E Pye, Ian A Taylor, Kyungjin Kim, Alan N Engelman, Baek Kim und 3 weitere

mBio · 28.02.2023 · 14 (1)

DOI: 10.1128/mbio.03560-22 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 28.02.2023. Verfasst von Matthew R Singer und 14 weiteren Autor:innen. Beteiligte Einrichtung: Chromatin Structure & Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom. Hauptthemen laut MEDLINE: HIV Integrase Inhibitors, HIV Infections. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Wellcome Trust, Cancer Research UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite the remarkable success of combination antiretroviral therapy, HIV-1 remains among the major causes of human suffering and loss of life in poor and developing nations. To prevail in this drawn-out battle with the pandemic, it is essential to continue developing advanced antiviral agents to fight drug resistant HIV-1 variants.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV Integrase InhibitorsHIV InfectionsHumansAllosteric RegulationAntiviral AgentsHIV Integrase

Stichwörter der Autor:innen

ALLINIBI-DHIV-1LEDGINPirmitegravirSTP0404allosteric inhibitorantiretroviral drugsintegrase

Substanzen

HIV Integrase InhibitorsAntiviral Agentsp31 integrase protein, Human immunodeficiency virus 1HIV Integrase

Autor:innen und Institutionen

  • Chromatin Structure & Mobile DNA Laboratory, The Francis Crick Institute, London, United Kingdom.
  • Division of Infectious Diseases, School of Medicine, University of Colorado, Aurora, Colorado, USA.
  • Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware, USA.
  • Macromolecular Structure Laboratory, The Francis Crick Institute, London, United Kingdom.
  • ST Pharm Co. Ltd., Seoul, South Korea.
  • Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

ORCID-Profile: Juan R Perilla, Mamuka Kvaratskhelia, Peter Cherepanov

Förderung

  • NIAID NIH HHS
  • Wellcome Trust
  • Cancer Research UK
  • Medical Research Council
  • NIGMS NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases
  • HHS | NIH | National Institute of General Medical Sciences

Zitieren

APA

Singer, M. R., Dinh, T., Levintov, L., Annamalai, A. S., Rey, J. S., Briganti, L., Cook, N. J., Pye, V. E., Taylor, I. A., Kim, K., Engelman, A. N., Kim, B., Perilla, J. R., Kvaratskhelia, M., & Cherepanov, P. (2023). The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function. mBio, 14(1). https://doi.org/10.1128/mbio.03560-22

Vancouver

Singer MR, Dinh T, Levintov L, Annamalai AS, Rey JS, Briganti L, et al. The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function. mBio. 2023;14(1). doi:10.1128/mbio.03560-22

BibTeX
@article{Singer2023,
  author = {Singer, Matthew R and Dinh, Tung and Levintov, Lev and Annamalai, Arun S and Rey, Juan S and Briganti, Lorenzo and Cook, Nicola J and Pye, Valerie E and Taylor, Ian A and Kim, Kyungjin and Engelman, Alan N and Kim, Baek and Perilla, Juan R and Kvaratskhelia, Mamuka and Cherepanov, Peter},
  title = {The Drug-Induced Interface That Drives HIV-1 Integrase Hypermultimerization and Loss of Function},
  journal = {mBio},
  year = {2023},
  volume = {14},
  number = {1},
  doi = {10.1128/mbio.03560-22}
}
Kostenlos starten →